
Opinion|Videos|March 11, 2024
MIRASOL trial and DESTINY-PanTumor02 Trial Overview
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG
3
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
4
How Effective and Safe Are GLP-1s for Weight Loss?
5
















































